Abstract-The total content and extent of processing of the +MSH and P-endorphincontaining
Introduction
brain. The processing of POMC in various tissues Proopiomelanocortin (POMC) is a 31000 dalton has been partially el&idated in multiple species, propeptide containing multiple functional with emphasis on the PE and ACTH-containing domains, including P-endorphin (PE), adreno-C-terminal domain; considerably less is known, corticotropin (ACTH), and OL-, p-, and y-melanohowever, about the processing of the y-MSH-contropins (MSHs). Although the majority of POMC taining N-terminal region. Tissue-specific processis found in the pituitary, it has also been found in ing of POMC in the monkey has received little other sites in lower concentrations, including the attention to date; as in other species, the processing of the N-terminal domain of POMC in primate neural tissue is not well understood. PateI-et al. in Date received 17 December 1987 our laboratories have recently cloned monkey Date accepted 21 December 1987 POMC, however, which should facilitate the 111 investigation of the processing of POMC in this periventricular grey are fully-processed (i.e., species based on the actual primary structure.
B-endorphin).
y-Melanotropin (+MSH) is found within the Because of the similarities between human and N-terminal domain of POMC, located between monkey POMC, the processing of monkey POMC the two major dibasic cleavage sites in the 16K is potentially relevant to human physiology. We N-terminal region (18) . Within this 16K region, previously reported on the content and partial ,3MSH is flanked by the extreme N-terminal processing of +MSH and PE in the monkey fragment of POMC and by joining peptide. ,3MSH pituitary (16). In this paper, we extend these can thus be theoretically found alone (molecular earlier observations, reporting content and comweight 3-4K), in association with joining peptide plete processing of both y-MSH and PE in monkey or with the extreme N-terminal fragment of pituitary and in selected brain regions.
POMC (molecular weight 9-11K) (22, 23), or as part of the intact 16 K N-terminal domain. ,xMSH shares considerable homology between the human and the monkey. The N-terminal region of the peptide (residues l-18) are completely conserved between the two species, an area that contains a potential dibasic cleavage site as well as a glycosylation signal. The C-terminal region of the peptide, however, shows considerable variability between the two species, and is only five residues in length in the monkey, compared with eight in the human (Pate1 et al., in preparation). The additional theorectical cleavage site (Arg-Arg, positions 13-14) located within +MSH in both the human and the monkey potentially yields a 12-residue peptide (+MSH), or an 11-residue, Camidated peptide, ,,MSH (15). Neither of these products, however, have been demonstrated in the human pituitary (11, 22, 23, 25, 26) .
Past efforts to determine the distribution and extent of processing of immunoreactive-y-melanotropin in primate neural tissue have focused on the pituitary. y-MSH has been found primarily as larger molecular forms (i.e., 9 K or larger) in the human pituitary (4, 22, 23, 25) . The distribution and extent of processing y-melanotropin and PE in the primate brain have been rarely reported. Osamura and colleagues (19) studied y-MSH in the human hypothalamus by immunocytochemistry and found that it tended to be colocalized with PE, and located primarily in the arcuate nucleus; these investigators also performed electron microscopic studies in this tissue, finding y-MSH localized in nerve terminals and in synapse-like structures, suggesting a possible neuromodulatory role for this peptide. Emson et al. (10) quantitated some POMC products, including PE but not y-MSH, in human brain, finding relatively increased amounts in the hypothalamus, amygdala, periventricular grey, substantia nigra, and the superior colliculus. Column chromatography revealed that the primary peptide forms in the hypothalamus and
Methods
Tissue preparation. Three post-menopausal Rhesus monkeys (Macaca mulatta) were anesthetized with pentobarbital and sacrificed by exsanguination. The brain and pituitary were rapidly removed and kept on wet ice for dissection. The pituitary was dissected into anterior and intermediate lobes. Due to the adhesion of the intermediate lobe to the other lobes, this tissue was somewhat contaminated by both anterior and posterior lobe tissue, hence, in this study, "intermediate" lobe actually refers to a mixture of all three pituitary lobes, although predominately intermediate lobe. The brain was dissected on wet ice into the following regions: hypothalamus, hippocampus, septum, colliculi, amygdala, striaturn, thalamus, midbrain, pons, medulla, and portions of frontal and occipital cortex. Immediately following dissection, individual tissue sections were frozen on dry ice and stored at -80°C.
Prior to extraction, individual tissue sections were weighed. Extraction was accomplished by subjecting tissue in 2ml acetone/O.1 N HCl (3:1, v/v) to a Polytron for 6Os, followed by a 1 ml rinse in acetone/HCl. The homogenate was centrifuged at 12OOOXg for 10 min and the supernatant collected and lyophilized. The dried extract was resuspended in 1 ml 1.0% formic acid.
Radioimmunoassays.
PE was assayed by a previously validated radioimmunoassay (1, 6). The antiserum is directed against a midportion of the PE molecule (residues 17-27), and is 100% crossreactive with all forms of SE, P-lipotropin, and POMC. +MSH was assayed using a radioimmunoassay that we have previously standardized (16, 17, 27 ). This antiserum is directed against a midportion region of bovine +MSH (residues 5-14), which shares complete homology with both monkey and human ,sMSH. This antisera does not cross-react with ,iMSH or +MSH.
,iMSH was quantitated by a recently developed radioimmunoassay.
The antiserum was raised in rabbits against synthetic ,iMSH (monkey, human, and bovine sequences are identical) conjugated to thyroglobulin.
The assay was performed in 150mM phosphate buffer, pH 8.2, containing 0.1% bovine serum albumin and 1.0% NaCl. Standards (synthetic Lys-,iMSH) and samples were added in 5OuL of 0.1% bovine serum albumin, pH 3.0. The antiserum was added in 1OOuL of buffer at a final titer of 1:3000. Due to difficulties of [i*'I] ,iMSH instability in this assay, the radioligand was rat [125I] Lys-,jMSH which was iodinated by the chloramine-T method (13); 20000 counts in 1OOuL of buffer containing 5% rabbit serum were added per tube. The assay was run in triplicate in a final volume of 25OuL under disequilibrium conditions for 48-72h at 4°C. Separation was by immunoprecipation following the addition of 15uL of sheep-anti-rabbit
IgG. This assay typically has an ICsO of 60 fmoles ,iMSWtube, and a sensitivity of 5 fmoles/tube. The antiserum has 57% cross-reactivity with synthetic human ,xMSH, 2% with ACTH1_23, and <O.l% with CX-MSH, B-MSH and BE. The intra-and inter-assay coefficients of variation are 5.3% and 8.4%, respectively.
Peptide measurement paradigm.
Aliquots of extracted tissue were lyophilized, resuspended in the appropriate solvent, and assayed for ,sMSH and BE immunoreactivity.
From those regions with sufficiently high concentrations of peptides (both pituitary lobes, hypothalamus, pons, septum, and colliculi), aliquots (300-4OOuL) were chromatographed on a Sephadex G-50 column (0.9 x 90cm). The column was developed in 1.0% formic acid, and 2.2ml fractions collected. Individual fractions were lyophilized, and resuspended in the appropriate solvent for PE, ,sMSH and ,iMSH quantitation by radioimmunoassay.
Aliquots of fractions contituting the void volumn from this column were pooled, lyophilized. resuspended in 300 uL of 1 .O% formic acid, and rechromatographed on a Sephadex G-100 column (0.9 X 9Ocm) in 1 .O% formic acid to better resolve larger molecular weight forms. The total amount of BE, Y3MSH and ,iMSH found in each observed peak from these two columns was calculated, and expressed as a percentage of the total immunoreactivity for that peptide for each region examined. Recovery of all peptides from the Sephadex columns exceeded 90%.
Concavalin A afinity chromatography. Fractions from Sephadex G-50 columns corresponding to a 4000 dalton form of ,sMSH from the pituitary were pooled and applied to a Concanavalin A-Sepharose 4B affinity column. This method has been used previously to demonstrate that bovine (24) and human (17) ,3MSH is glycosylated. Briefly, samples were resuspended in 5OOuL of buffer and applied to a 5OOuL affinity column. Following extensive washing, glycosylated material was eluted by increasing concentrations of cr-methyl-D-mannopyranoside and by acetic acid. 1 ml fractions were collected from this column and lyophilized. +MSH content was determined in each fraction by radioimmunoassay.
Results
Peptide content. The total amount of ,jMSH and BE immunoreactivity found in the individual brain and pituitary regions is summarized in Table 1 . Both ,xMSH and PE were found concentrated in the two pituitary lobes, although significant levels were also detected in the hypothalamus, colliculi, septum and pons. Lower levels were detected in the remaining brain regions. There was no significant difference between total immunoreactive (IR)-PE and IR-,sMSH in any given tissue. Inspection of Table 1 reveals fairly large standard errors, partially due to the small number of animals studied.
Processing of y-MSH in brain and pituitary
regions. The percentage of ,sMSH immunoreactivity found as fragments of various molecular weights was calculated from Sephadex column chromatography, and is summarized in Table 2 . As shown in the representative elution profiles of y-MSH in the "intermediate" and anterior lobes of the pituitary in the top panels of Figures 1 and 2 , IR-.,aMSH was found in peaks of 4K. 9K, 16K (POMC N-terminal to ACTH), and in the void volume (presumably intact POMC). In all studied tissues, most IR-+MSH was found as 4K and 9K forms. In the anterior lobe of the pituitary (Fig 2) , the predominant form was 9 K. In "intermediate" lobe (Fig 1) and the various brain regions, however, the 4K form either predominated or was nearly equal to the amount of 9 K ,sMSH. In spite of the obvious extent of processing of ,sMSH to 4 K and 9K forms in all tissues, a significant amount (up to 25%) of +MSH immunoreactivity was found as the 16K form..,iMSH was not found in any of the tissues listed m Table 2 .
Processing of @LT. As a comparison control, the extent of processing of PE immunoreactivity was determined in parallel with ,aMSH. These results are summarized in Table 3 . As shown in representative elution profiles (lower panels, Figs 1 and 2), BE immunoreactivity was found as BE, B-lipotropin, and a larger form (presumably POMC). Additionally, some was found as a 5 K form, which is presumably BE extended to N-terminally by part or all of B-MSH. In anterior pituitary (Fig 2) , 62% of IR-BE was found to exist as B-lipotropin; in contrast, in "intermediate" lobe (Fig 1) and the various brain regions, most was found as the smaller, more processed forms (BE and the 5K form). 
Extent of Glycosylation of ,MSH.
A representative profile of pituitary-derived 4K ,3MSH from a Concanavalin A affinity column is shown in Figure  3 . Similar to findings in human plasma (17) and bovine pituitary (24), most (76 5 10%) of this material is glycosylated. As a control, less than 10% of synthetic, nonglycosylated, human +MSH is retained by these affinity columns.
Discussion
The largest concentrations of +MSH and PE were found in the anterior and "intermediate" lobes of the pituitary, although significant amounts were also found in the hypothalamus, pons, septal region, and colliculi. This is in agreement with previous reports of substantial amounts of ?I-MSH in the human pituitary (4, 22, 23, 25) . Although the distribution of ?I-MSH has not been determined in the primate brain, it has been studied in the rat brain immunohistochemically (5, 14) . These studies have demonstrated that y-MSH parallels the distribution of PE; y-MSH ceh bodies are localized in the intermediate lobe of the pituitary, corticotrophs in the anterior lobe, and the arcuate nucleus. Kawai et al. (14) also demonstrated a collection of y-MSH-containing neurons in the nucleus commissuralis. y-MSH-immunoreactive nerve fibers have been demonstrated within the diencephalon, pons, hypothalamus, amygdala, and the central grey of the midbrain.
Several other investigators have studied the distribution of other POMC products in brain. although ?I-MSH itself was not explored. DuPont and co-workers (8) quantitated gE in bovine and rat brain, finding the largest concentration in the hypothalamus of both species, followed by the periaqueductal grey. thalamus and amygdala in the rat, and by the pons and septum in bovine tissue. Multiple POMC products, including PE, ACTH, and a-MSH were studied in the human brain (lo), with significant amounts found in the hypothalamus, amygdala, periventricular grey, substantia nigra, and superior colliculus. The distribution of ,aMSH and PE in the monkey agrees well with these studies in other species; the largest amounts of immunoreactivity are found in tissues rich with POMC-containing neurons (pituitary and hypothalamus), and relatively less peptide is found in tissues associated with fiber tracts, The processing of y-MSH in the monkey pituitary appears to be similar to the processing in other species. For example, ?I-MSH is processed to a smaller form (glycosylated ,sMSH), and is also found as a larger form (lo-11 K) in rat (20) and bovine pituitaries (24). In both species, the smaller form predominates in the intermediate lobe, whereas the somewhat larger form is preferentially stored in the anterior lobe, in agreement with our results in the monkey. y-MSH has also been studied in the human pituitary. Only a larger form NEUROPEPTIDES of ?I-MSH-immunoreactivity is found, however (22, 23, 25) , which in the human corresponds to +MSH extended with the extreme N-terminal fragment of POMC (22, 23) . Based on findings in other species, 9 K ,3MSH is likely ,sMSH extended with the extreme N-terminal fragment of POMC, although it is possible that 9K form in monkey is +MSH extended by joining peptide. It is of note that in the anterior lobe of the monkey, some of this intermediate-sized product is further processed to 4K .xMSH, a processing step that does not appear to occur in human pituitary tissue. 4K .sMSH is likely glycosylated ,sMSH, as found in other species. Because of slight differences in the primary structure of monkey POMC compared to that of rat and human, the identification of the 4K and 9 K fragments is tentative. While there are two minor amino acid differences between the human and monkey sequences of the extreme N-terminal fragment of POMC, differences in joining peptide are more substantial. In monkey joining peptide, positions 11-12 are Arg-Gly, compared to Cys-Gly in the human (and absent in the rat), resulting in an additional possible single basic cleavage site. 4K ,sMSH in the monkey, then, could conceivably also be deglycosylated ,jMSH extended C-terminally by the first eleven residues of joining peptide.
PE is processed similarly to y-MSH in the monkey pituitary; the "intermediate" lobe tends to store more processed forms of BE (PE and a 5 K form), and the anterior lobe @lipotropin. Of interest is that the anterior lobe is able to further process B-lipotropin to smaller forms in significant amounts, in agreement with a previous report (7). An unexpected finding is the 5 K-sized form of BE. This fragment contains BE, and is presumably extended N-terminally by some or all of B-MSH. This may represent an alternate processing pathway for l3E in some tissues in the monkey.
The processing of y-MSH and PE in various brain regions was similar to that in the intermediate lobe of the pituitary, with the primary products identified as a mixture of the most processed form and the immediate precursor to this product for both peptides (+MSH and the 9K form, and l3E and the 5K form). There have been few reports detailing the processing of ,xMSH in brain regions. Emeson and Eipper (9) demonstrated that the majority of y-MSH in rat hypothalamus is glycosylated +MSH. Although v-MSH was not studied, Emson et al (10) demonstrated that the majority of l3E immunoreactivity in the human hypothalamus and periventricular grey is BE-sized. The finding in monkey brain of substantial processing of POMC to +MSH and PE agrees well with these two reports in other species.
These results in the monkey agree fairly well with the limited y-MSH processing data published for other species. Several notable differences. however, are apparent from our data. In the human pituitary, y-MSH processing appears to stop at the 9K form, and no smaller forms are found. In the monkey, however, significant amounts of glycosylated ,jMSH are found, indicating an additional processing step absent in the human. A second unexpected finding was the processing of IR-PE to a 5K form; as previously mentioned, this may represent an alternate processing route for the C-terminal domain of POMC in the monkey. Although r-MSH has a peripheral role potentiating ACTH-induced adrenocortical steroidgenesis (2, 3, 12, 21) , its role in the central nervous system is unknown. It has been demonstrated by electron microscopic studies (19) to exist in nerve terminals and synapse-like structures. It exists in processed forms in various brain regions, as we and others have demonstrated. These data suggest that y-MSH may have a neuromodulatory role in the central nervous system.
